Optimieren Sie Ihre Suche

  • Bücher (12)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

Öner tulum william lazonick (12 Ergebnisse)

Autor: 
Mit der Detailsuche verfeinern
  • Sprache: Englisch

    Verlag: Cambridge University Press, GB, 2025

    1009707981 / 9781009707985

    • Softcover

    Anbieter: Rarewaves.com USA, London, LONDO, Vereinigtes KönigreichRarewaves.com USA

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 29,91

     Versand gratis 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: 2 verfügbar

    Paperback. Zustand: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.…

  • Sprache: Englisch

    Verlag: Cambridge University Press, GB, 2025

    1009707981 / 9781009707985

    • Softcover

    Anbieter: Rarewaves USA, HEBRON, KY, USARarewaves USA

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 30,40

     Versand gratis 
    Versand innerhalb von USA

    Anzahl: Mehr als 20 verfügbar

    Paperback. Zustand: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.…

  • Sprache: Englisch

    Verlag: Cambridge University Press, 2025

    1009707981 / 9781009707985

    • Softcover

    Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 35,03

    EUR 11,99 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: 2 verfügbar

    Paperback. Zustand: Brand New. 96 pages. 6.00x0.22x9.00 inches. In Stock.

  • Sprache: Englisch

    Verlag: Cambridge University Press, 2022

    1009278169 / 9781009278164

    Serie: Buch 4 von 15 - Elements in Reinventing Capitalism

    • Softcover

    Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes KönigreichGreatBookPricesUK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Wie neu

    EUR 30,68

    EUR 17,98 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: As New. Unread book in perfect condition.

  • Sprache: Englisch

    Verlag: Cambridge University Press, 2022

    1009278169 / 9781009278164

    Serie: Buch 4 von 15 - Elements in Reinventing Capitalism

    • Softcover

    Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes KönigreichGreatBookPricesUK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 32,69

    EUR 17,98 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New.

  • Sprache: Englisch

    Verlag: Cambridge University Press, GB, 2025

    1009707981 / 9781009707985

    • Softcover

    Anbieter: Rarewaves USA United, HEBRON, KY, USARarewaves USA United

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 31,35

    EUR 45,37 Versand 
    Versand innerhalb von USA

    Anzahl: Mehr als 20 verfügbar

    Paperback. Zustand: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.…

  • Sprache: Englisch

    Verlag: Cambridge University Press, GB, 2025

    100970799X / 9781009707992

    • Hardcover

    Anbieter: Rarewaves.com USA, London, LONDO, Vereinigtes KönigreichRarewaves.com USA

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 88,68

     Versand gratis 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Hardback. Zustand: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.…

  • Sprache: Englisch

    Verlag: Cambridge University Press, 2025

    100970799X / 9781009707992

    • Hardcover

    Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes KönigreichGreatBookPricesUK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 81,77

    EUR 17,98 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New.

  • Sprache: Englisch

    Verlag: Cambridge University Press, 2025

    100970799X / 9781009707992

    • Hardcover

    Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes KönigreichGreatBookPricesUK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Wie neu

    EUR 83,01

    EUR 17,98 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: As New. Unread book in perfect condition.

  • Sprache: Englisch

    Verlag: Cambridge University Press, GB, 2025

    1009707981 / 9781009707985

    • Softcover

    Anbieter: Rarewaves.com UK, London, Vereinigtes KönigreichRarewaves.com UK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 27,74

    EUR 77,92 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: 2 verfügbar

    Paperback. Zustand: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.…

  • Sprache: Englisch

    Verlag: Cambridge University Press, 2025

    100970799X / 9781009707992

    • Hardcover

    Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 118,29

    EUR 11,99 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: 2 verfügbar

    Hardcover. Zustand: Brand New. 96 pages. 6.00x0.25x9.00 inches. In Stock.

  • Sprache: Englisch

    Verlag: Cambridge University Press, GB, 2025

    100970799X / 9781009707992

    • Hardcover

    Anbieter: Rarewaves.com UK, London, Vereinigtes KönigreichRarewaves.com UK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 81,78

    EUR 77,92 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Hardback. Zustand: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.…